H. Lundbeck A/S
HLUN-A
Ранг среди акций
#3072
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Цена акции
$7.07
Рыночная капитализация
$5.91B
Изменение (1 день)
-4.56%
Изменение (1 год)
28.57%
Страна
DK
Торговля H. Lundbeck A/S (HLUN-A)
Категория
Healthcare
История дроблений акций H. Lundbeck A/S (HLUN-A)
Акции H. Lundbeck A/S (символ: HLUN-A) прошли через 0 дроблений.
Последнее дробление произошло Oct 21, 2026.
Одна акция HLUN-A, купленная до Oct 21, 2026, сейчас соответствует 0 акциям HLUN-A.
Последнее дробление произошло Oct 21, 2026.
Одна акция HLUN-A, купленная до Oct 21, 2026, сейчас соответствует 0 акциям HLUN-A.
Список дроблений акций
| Год | Дробление | Коэффициент | Суммарный коэффициент |
|---|---|---|---|
| Недостаточно данных для указанных дат. | |||
Дробления акций аналогичных компаний или конкурентов
| Компания | Количество дроблений акций | Суммарный коэффициент | Страна |
|---|---|---|---|
| 0 | - |
US
|
|
| 0 | - |
SE
|
|
| 0 | - |
FR
|
|
| 0 | - |
US
|
|
| 0 | - |
IT
|
